It's hard for pharmaceutical companies to buy with volume

The Chinese pharmaceutical market in 2020 will be a difficult time for all pharmaceutical companies, not to mention.
new path seems to be the only option, but there is still a lot of obscurity about how to go.
jun don't see: some of the barefoot who rushed past the evaluation of metformin, just out of the mountains hit the iceberg, profit there are too many variables.
this paper, the author is inspired by some research data and views, talk about pharmaceutical companies to adapt to the collection policy, what should be done quickly? "Influenced by the centralized drug procurement policy, "no products to do" has become the topic of many pharmaceutical agents in 2020.
exclusive dosage form chemicals, high-quality chemical generics, auxiliary drugs, exclusive Chinese medicine injections are in the future collection of "hunting" range.
product line more single domestic manufacturers urgently need to introduce products to supplement the existing product line.
time, the whole industry is recruiting BD, pay attention to do product introduction.
BD's shortage of people, project transactions reached a new high.
research and development-oriented enterprises may not be able to fully understand the policy and market, marketing-oriented enterprises hope that research and development funds should not be invested too much.
the generics business, small and medium-sized companies are trying to avoid the domestic giant's product line.
", pharmaceutical enterprises to adapt to the collection policy to move up the author refers to the action, forced by the absolute strong position of strategic buyers, is to seek in a weak environment, some like-minded pharmaceutical enterprises actively seek to live, with rich, pragmatic cooperation in innovative products, marketing, with a transparent and open position to welcome all relevant departments for inspection, flight inspection.
From a strategic point of view, this way of acting from industry and enterprise has four characteristics: first, it is two different things from the traditional vilified and arbitrage, second, the relevant participants form pragmatic and effective endowment cooperation at the critical moment of life and death, third, there is no need to form a unified, general, formal alliance, and fourth, it emphasizes the two links of research and development, production and commerce.
from a tactical point of view, this relationship does not take shape naturally and needs to be driven by bold people like a collection policy.
, who will advocate pharmaceutical companies have to move to change one is from the collection policy has benefited a lot of domestic generic drug giants.
you know, today's collection policy is like the beginning of the construction of high-speed rail, as a relationship between 1.4 billion people of another epic project, the future not only city and county, but also rural.
the domestic generics giant sitting in the first carriage of the opening ceremony, theoretically to the building to build the last kilometer, which is not only a solemn commitment to the policy of the necessary task, but also the market, users pay attention to the feasible business.
In case the product pipeline is missing, we will go to the market Taobao old drug renovation (over-consistent evaluation or improvement of new drugs), in case the research and development efficiency is not good, please small and medium-sized enterprises to help is not a shame.
second is in the collection policy under the profit-making system of the collapse of the enterprise.
you know, burning sticks are hot and always unbalanced.
is like a drug collection policy, strategic buyers hold the buyer's power, do not obey its formulation of competitive negotiations, recruitment rules, really can not ah.
but the scenery is no longer the same between the pharmaceutical companies, it does not apply to that set of discourse system.
we all do medicine, each other's strengths and weaknesses and the length of value who is not clear? Talk about winning to continue to talk, talk about not winning and perhaps there are better partners waiting, to be excavated.
we advise pharmaceutical companies that are temporarily out of power not to be discouraged and to catch up in the right direction.
is the development and reform sector, which once held the power in this area.
Don't look at the harvesting policy today is hot and booming, but the strategic buyers continue to cattle on the basis of the development of the industry, lies in the successful transition of old production capacity to new products.
Between drug research and development, production, commercial links, between the gains and losses between enterprises, between the lost and lost enterprises, there is certainly a set of free cooperation between the market trigger mechanism, the industry also hopes that the development and reform departments can help enterprises in the three-medical linkage policy environment to point a few clear roads, if you can match some funds better.
fourth is to see the international changes in the trend of national sovereignty funds.
know that since 2013, China's tertiary industry as a proportion of GDP for the first time more than the secondary industry, in the first half of 2020 China's industrial economy as a proportion of GDP only 33%.
, the nation's most populous and financially powerful state, has passed legislation that would allow the state to work with industry to produce and distribute generics.
based on China's raw materials, generic drug production capacity is large but not strong, the collection policy can also be regarded as the baton of structural adjustment, and the investment sector may consider the introduction of more in line with the pharmaceutical, pharmaceutical business industrial transformation opportunities.
Three, international cooperation is an opportunity and a risk and a challenge" At this juntoun, Keystone Pharmaceuticals official Xuan and Pfizer reached nearly 500 million strategic cooperation, including: Pfizer's $200 million equity investment in Keystone Pharmaceuticals; In Chinese mainland's exclusive commercialization rights, Keystone Pharmaceuticals is entitled to nearly $300 million in milestone payments and additional tiered royalties, and the two parties jointly select concept-proven tumor products developed jointly in Greater China, possibly from Pfizer or imported from third parties.
PS: The PD-L1 developed by Pfizer and Merck is not listed in China and does not compete directly;
" everything is specific, from the current observation, international cooperation mainly includes: First, the purchase of multinational pharmaceutical companies' products commercial rights, second, the commercial rights of their products to multinational pharmaceutical companies;
think that these three ways of domestic enterprises are the pros and cons of risk ranking is: the disadvantages gradually decline, the benefits gradually rise.
't always tall.
the first form of cooperation: the right to commercialize the purchase of products from multinational pharmaceutical companies.
with the exception of some multinational pharmaceutical companies that do not have marketing networks in China, why don't multinational pharmaceutical companies take the lead in organizing the sale of the product in China? I am afraid the reasons include: First, the relationship between international prices, multinational pharmaceutical companies do not want to be targeted by domestic or international strategists;
a second form of cooperation: the commercialization of its products to multinational pharmaceutical companies.
think: is the pros and cons, mainly look at the development stage of domestic enterprises, strength and strategy.
, for example, is a new need to work with Pfizer or other peers with the ability to commercialize their products.
but if domestic enterprises will be the main products, ace products are poured to multinational pharmaceutical companies, it may lack of policy sensitivity, loss of control of the market.
a third way of working together: in research and development.
This means that many domestic pharmaceutical enterprises research and development departments, personnel not only for the domestic generic drug giants, including larger enterprises to bear the division of labor, but also in the global pharmaceutical research and development industry chain introductory art.
's not hard to understand.
After all, the cornerstone of the pharmaceutical industry, Baiji Shenzhou has innovative drug talent, they also have improved drugs, drug evaluation talent, the future can also find the right team and talent from the market.
ways to see through death include thinking about reso living.
of the above three ways of cooperation, is the last way for many domestic pharmaceutical companies, but also many enterprises with the current strength of the road can not be touched for a while.
but even so, it helps to think about it and look at it.
through the calculation, we understand that no matter what, pharmaceutical companies must pay attention to the clinical efficacy of drugs, must be in line with the policy of rational drug use and the market.
believe that: in the collection of the target, there are promising business changers, creators will appear, not who's famous, not big fish eat small fish.
fourth, the calculation of pharmaceutical companies and pharmaceutical business re-ingenuity first to say the power of pharmaceutical business.
still to the cornerstone of pharmaceutical and Pfizer's strategic cooperation as an example, in fact, there is strength, thinking of the pharmaceutical business can come to fight with Pfizer, grab a grab.
even if you can't get this PD-L1, you can talk about other businesses, commercial rights to products, milestone payments, and so on.
pharmaceutical business only need to pay attention to: First, compliance with the law;
we always think: at home, the pharmaceutical business than the most marketing-oriented pharmaceutical companies are in line.
policy is a one-vote, two-vote system.
pharmaceutical business want to invest in research and development, production, pharmaceutical companies want to dig a good use, efficient commercial team.
but they do have a lot of temperament and trust gaps.
and contracts, laws, and policies can be resolved in a timely manner.
On the one hand, pharmaceutical companies should have a price reduction cycle for any product risk management concept, to strictly control the cost and profit of the marketing process;